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Objective: To evaluate the impact of onabotulinumtoxinA on individual domains of the
quality of life questionnaires in a pooled analysis of two phase 3 trials in overactive bladder
patients with urinary incontinence who were inadequately managed by ≥1 anticholinergic.
Methods: Patients received intradetrusor injections of onabotulinumtoxinA 100U
(n = 557) or placebo (n = 548). The proportions of patients with a positive response
(condition “greatly improved” or “improved”) on the Treatment Benefit Scale, and
changes in Incontinence Quality of Life scores and King’s Health Questionnaire domain
scores were analyzed in the overall population and subgroups with clean intermittent
catheterization use and urinary tract infection status during the first 12 weeks of
treatment. Responses to individual King’s Health Questionnaire items were also assessed.
Results: Significantly greater proportions of onabotulinumtoxinA-treated patients
achieved positive Treatment Benefit Scale response versus placebo (61.8% vs 28.0%;
P < 0.001). OnabotulinumtoxinA showed significantly greater improvements versus
placebo in Incontinence Quality of Life total (22.5 vs 6.6), Incontinence Quality of Life
subscale scores and all domains of the King’s Health Questionnaire. Notably, a similar
trend was observed regardless of clean intermittent catheterization/urinary tract infection
status. Additionally, onabotulinumtoxinA resulted in significantly greater improvements
than the placebo in practical aspects of patients daily lives, including pad use, need to
change undergarments, sleep, relationship with partner and work life/daily activities.
Conclusion: In overactive bladder patients with urinary incontinence, onabotulinu-
mtoxinA 100U demonstrated significant improvements across the individual domains of the
quality of life questionnaires, regardless of clean intermittent catheterization or urinary tract
infection status, and provided a positive impact on practical aspects of patients’ daily lives.
Key words: health-related quality of life, onabotulinumtoxinA, overactive bladder,
patient-reported outcomes, urinary incontinence.
Introduction
OAB is a common condition prevalent in 12–17% of the population, and is deﬁned as urinary
urgency, usually accompanied by frequency and nocturia, with or without UUI.1–5 OAB
symptoms have a negative effect on patients’ HRQOL, including decreased work productivity,
sexual satisfaction and performance of routine daily tasks, poorer sleep quality and increased
feelings of depression.6–8
First-line therapeutic options, such as behavioral modiﬁcations, bladder retraining and pad
use, are often inadequate.9,10 Pharmacological treatment with anticholinergic therapy is often
discontinued because of insufﬁcient efﬁcacy or intolerable side-effects.11–14 Thus, there is a
need for alternative treatments that can effectively reduce the burden of OAB symptoms and
improve HRQOL in patients who are inadequately managed by anticholinergic therapy.
Two large, placebo-controlled, phase 3 trials independently showed that onabotA
signiﬁcantly reduces all symptoms of OAB, including episodes of incontinence, urgency, mic-
turition and nocturia, and improves HRQOL outcomes in OAB patients with UI who were
inadequately managed by ≥1 anticholinergic.15,16 This pooled analysis of the two trials had
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the following aims: (i) assess all individual HRQOL
domains/subscales in the overall population; (ii) evaluate
whether use of CIC or the presence of UTI affects HRQOL
outcomes or patient perception of treatment beneﬁt; and (iii)
assess speciﬁc items on self-reported patient questionnaires
that have practical implications for patients’ daily lives,
including pad use, work life, relationship with partner, mental
well-being and sleep quality.
Methods
Study design
Details on the two phase 3 placebo-controlled trials
(ClinicalTrials.gov identiﬁers: NCT00910845 and
NCT00910520) have been previously published.15,16 Brieﬂy,
the two trials enrolled OAB patients (n = 1105) who had expe-
rienced ≥3 UUI episodes over a 3-day period and ≥8 micturi-
tions per day. Patients were randomized 1:1 to receive 20
cystoscopic intradetrusor injections (0.5 mL/injection) of ona-
botA 100U or placebo, sparing the trigone. Patients partici-
pated in the study for 24 weeks, and could receive retreatment
with onabotA 100U from 12 weeks onwards if requested by
the patients and if they had ≥2 UUI episodes as recorded in a
3-day diary. Dosing and results reported in the present study
are speciﬁc to onabotA. This formulation is not interchangeable
with other botulinum toxin products, and Units cannot be con-
verted using a dose ratio. All patients had been inadequately
managed by ≥1 anticholinergic, and those with a predominance
of stress UI were excluded.
In the phase 3 trials, the change from baseline at week 12
in UI episodes/day (co-primary endpoint) after treatment with
onabotA, and changes from baseline in other OAB symptoms
of urgency, micturition and nocturia were assessed as mea-
sures of clinical efﬁcacy.15,16 For this analysis, data were
pooled from the two trials to assess patient-reported outcomes
at week 12 after the ﬁrst treatment.
Patient-reported outcome measures
Patients recorded their perception of treatment beneﬁt at each
post-treatment visit using the one-item TBS (co-primary
endpoint), rating their condition as “greatly improved,”
“improved,” “not changed” or “worsened.”17 The impact of
OAB on patients’ HRQOL was assessed at week 12 post-
treatment using the following two validated patient question-
naires: the I-QOL Instrument18 and the KHQ.19
The I-QOL is a self-administered, disease-speciﬁc, 22-item
questionnaire designed to measure the impact of UI on
patients’ lives. It provides a total summary score (prespeciﬁed
secondary endpoint) ranging from 0 to 100, with higher
scores reﬂecting better HRQOL (sum of all 22 individual
items) plus three of the following domain scores: Avoidance
and Limiting Behavior, Psychosocial Impact and Social
Embarrassment. The KHQ is an OAB-speciﬁc questionnaire
designed to measure the impact of OAB on patients’ HRQOL
on the multi-item domains of Role Limitations (prespeciﬁed
secondary endpoint), Social Limitations (prespeciﬁed sec-
ondary endpoint), Physical Limitations, Personal Relation-
ships, Emotions, Sleep/Energy and Severity/Coping measures,
and two single-item domains of General Health perception
and Incontinence Impact. Symptom scores range from 0 to
100, with lower scores indicating better HRQOL. The prede-
ﬁned clinically relevant change from baseline (MID) in these
HRQOL measures was based on published literature, and
determined a priori as follows: a +10-point increase for the I-
QOL and a 5-point decrease for the KHQ.20,21 The practical
impact of OAB symptom reduction on patients’ daily lives
was further investigated by assessing patient responses at
week 12 post-treatment to speciﬁc questions on the KHQ
questionnaire that focused on pad use, changing underclothes,
sleep quality, worn out/tired feelings, work/activities outside
the home, depressed feelings and relationship with partner
(Table S1).
Statistical analysis
The proportion of patients reporting a positive response (rat-
ing their condition as “greatly improved” or “improved”) on
the TBS were evaluated in the overall pooled population by
treatment, and in subgroups of patients by CIC (use/non-
use) and UTI status (presence/absence) using the Cochran–
Mantel–Haenszel v2 method with the dichotomized number
of baseline UUI episodes (≤9 or >9) as a stratiﬁcation fac-
tor. The proportion of patients who improved on the KHQ
severity measures and speciﬁc items at week 12 after treat-
ment was assessed in the overall pooled population using
the same Cochran–Mantel–Haenszel method as for the TBS
analysis.
Changes from baseline in I-QOL total summary score,
I-QOL subscale scores and KHQ domain scores were assessed
in the overall pooled population using an ANCOVA model, with
treatment group as the factor, and baseline scores, baseline
UUI episodes (≤9 or >9) and site as covariates. As the sub-
group analyses by CIC use/non-use and UTI status (presence/
absence) were post-hoc and the sample sizes were small, statis-
tical comparisons between these groups are not reported.
Results
Baseline demographics and disease
characteristics
The overall pooled population comprised 1105 patients ran-
domized to onabotA 100U (n = 557) or placebo (n = 548).
Baseline demographics and disease characteristics were bal-
anced between the treatment groups (Table 1). The mean age
was 60.4 years; 87.8% were female, mean duration of OAB
was 6.1 years and patients reported a mean of 5.4 UI epi-
sodes/day. The patients’ I-QOL total and subscale scores at
baseline ranged from 24.4 to 42.9, whereas KHQ domain
scores ranged from 31.3 to 83.4 (Table 1).
Outcome measures
As previously published, treatment with onabotA 100U
resulted in signiﬁcant improvements in patients’ OAB symp-
toms compared with the placebo, with reductions from base-
line at week 12 in mean daily episodes of UI (2.80 vs
0.95), urgency (3.30 vs 1.23), micturition (2.35 vs
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0.87) and nocturia (0.49 vs 0.24; P < 0.001 vs placebo
for all parameters).15,16 Signiﬁcantly higher proportions of
onabotA- than placebo-treated patients achieved a 100%
reduction in UI episodes (i.e. became “dry”; 27.1% vs 8.4%;
P < 0.001).22
Overall pooled population
A signiﬁcantly higher proportion of onabotA-treated patients
reported a positive response on the TBS compared with pla-
cebo (61.8% vs 28.0%; P < 0.001; Fig. 1). Signiﬁcantly
greater improvements in patients’ HRQOL scores were
observed after treatment with onabotA compared with pla-
cebo (I-QOL total: 22.5 vs 6.6; Avoidance and Limiting
Behavior: 23.7 vs 6.6; Psychosocial Impact: 20.5 vs 6.3;
Social Embarrassment: 23.8 vs 6.8; P < 0.001 vs placebo
for all; Fig. 2a). Improvements in I-QOL total and all sub-
scale scores with onabotA treatment were three to four
times those with placebo, and two times the MID, whereas
none of the improvements observed with placebo exceeded
MID (Fig. 2a).
Improvements from baseline in KHQ Role and Social Lim-
itations domain scores were also signiﬁcantly greater with
onabotA compared with placebo (Role Limitations: 25.4 vs
3.7; Social Limitations: 16.8 vs 2.5; P < 0.001 vs pla-
cebo for both; Fig. 3a). The same trend was observed for all
other KHQ domain scores, with magnitudes of improvement
with onabotA ranging from three to seven times the placebo
and two to ﬁve times the MID, apart from General Health
(Fig. 3a).
The negative impact and bother of urinary symptoms on
patients’ daily lives was signiﬁcantly reduced at week 12
after treatment with onabotA compared with placebo (Fig. 4).
Compared with responses at baseline, a signiﬁcantly higher
proportion of onabotA-treated patients versus placebo
reported a decrease in the frequency of pad use (37.6% vs
15.3%) and changing underclothes (54.9% vs 25.7%) at
week 12 (P < 0.001 vs placebo for both; Fig. 4). Signiﬁcant
improvements were also observed with onabotA versus pla-
cebo in other KHQ individual items, including sleep, tired/
worn out feelings, work life/daily activities, depressed feel-
ings due to bladder problems and relationship with partner
(P < 0.001 vs placebo for all; Fig. 4).
Subgroups by CIC (use/non-use) and UTI status
(presence/absence)
During the ﬁrst 12 weeks (placebo-controlled period), CIC
for urinary retention was initiated in 31 of 557 patients
(5.6%) in the onabotA group compared with one of 548
patients (0.2%) in the placebo group. CIC was performed at
an average frequency of 2.3 times/day with a median dura-
tion of 8.3 weeks in the onabotA group, and 4.7 times/day
with a median duration of 2.6 weeks in the placebo group.
During the ﬁrst 12 weeks of treatment, UTI occurred in 99 of
557 patients (17.8%) in the onabotA group and in 30 of 548
Table 1 Baseline demographics and disease characteristics (overall
pooled population)
Characteristic Placebo (n = 548)
OnabotA 100U
(n = 557)
Age (years) 60.1  13.6 60.6  14.2
Female sex, n (%) 474 (86.5) 496 (89.0)
Duration of OAB (years) 6.1  7.1 6.0  7.1
Prior anticholinergic use 2.5  1.5 2.4  1.5
UI episodes/day 5.4  3.6 5.5  3.7
Urgency episodes/day 8.3  4.1 8.8  4.7
Micturition episodes/day 11.5  3.4 12.0  4.1
Nocturia episodes/day 2.0  1.4 2.2  1.5
I-QOL scores
Total summary 34.7  18.5 34.1  19.0
Avoidance and Limiting Behavior 31.6  16.9 31.2  17.1
Psychosocial Impact 42.9  23.8 42.3  24.8
Social Embarrassment 25.0  21.1 24.4  20.8
KHQ multi-item domain scores
Role Limitations 61.2  29.0 65.4  29.0
Social Limitations 42.4  30.6 44.8  31.3
Physical Limitations 64.9  29.9 67.0  28.5
Personal Relationship 36.2  35.9 37.9  35.5
Emotions 55.3  29.3 56.0  31.3
Sleep/Energy 65.3  26.6 64.7  27.0
Severity/Coping 64.6  23.1 65.7  22.8
KHQ single-item domain scores
General Health Perception 32.2  23.9 31.3  23.8
Incontinence Impact 83.4  23.1 83.3  24.7
Data are mean  SD unless otherwise indicated.
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Fig. 1 Proportion of patients with a positive
response (their condition “greatly improved” or
“improved”) on the TBS in the overall pooled
population and subgroups by CIC use and UTI
status. *P < 0.001 versus placebo. Error bars
represent 95% confidence intervals. The n values
denote the number of patients with data available
at week 12.
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patients (5.5%) in the placebo group, with a median time to
onset of 4.7 and 6.2 weeks, respectively.
The proportion of patients with a positive TBS response
with onabotA treatment was 61.8% in the overall population,
and was similar among onabotA-treated patients with or with-
out CIC use (61.3% and 61.8%, respectively; Fig. 1).
Although TBS response was slightly lower in onabotA-trea-
ted patients with UTI (52.5%) versus those without (63.8%),
it was consistently greater for the onabotA group compared
with placebo, regardless of UTI status (Fig. 1).
Improvements in I-QOL total score with onabotA were
two times the MID, and similar in magnitude in the over-
all pooled population (22.5), the group with CIC use
(21.5) and the group without (22.5; Fig. 2). Slightly smal-
ler improvements in I-QOL total score were noted in ona-
botA-treated patients with UTI compared with those
without UTI (16.8 vs 23.7); however, regardless of UTI
status, markedly larger improvements (two times the MID)
were noted with onabotA treatment compared with placebo
(Fig. 2b).
Improvements from baseline were up to ﬁve times the
MID in the prespeciﬁed KHQ domains of Role Limitations
and Social Limitations (Fig. 3b), and in all other
domains except General Health (Table 2), regardless of CIC
use. There was a trend for smaller improvements in all KHQ
domain scores in onabotA-treated patients with UTI
compared with those without UTI; however, the improve-
ments were two to ﬁve times the MID across all the
domains except General Health (Fig. 3b; Table 2) in both
groups.
Discussion
Given the high burden of symptom bother in patients with
OAB who are untreated,6–8 and the high discontinuation rates
with anticholinergic therapies,11–14 it is important to evaluate
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Fig. 2 Change from baseline in (a) I-QOL total
summary and three subscale scores in the overall
pooled population, and (b) I-QOL total summary
score in the subgroups by CIC use and UTI status.
*P < 0.001 versus placebo. Error bars represent
95% confidence intervals. The n values denote the
number of patients with data available at
week 12.
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the impact of OAB treatments on patients’ lives. This
pooled analysis of two large, randomized, phase 3, placebo-
controlled studies shows that the OAB symptom improve-
ment previously shown with onabotA 100U is accompanied
by a practical beneﬁt on patients’ daily lives, with signiﬁcant
improvements across multiple patient-reported outcomes.
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Signiﬁcantly greater improvements were seen with onabotA
than placebo in the perception of treatment beneﬁt, and in all
I-QOL and disease-speciﬁc KHQ domains. Notably, these
improvements were clinically meaningful regardless of the
use of CIC or the presence of UTI.
Previous studies have shown that, compared with the gen-
eral population, patients with OAB have higher rates of dis-
satisfaction with their sleep quality, work life and sexual
function, and express greater feelings of depression and
stress.7,8 Our analysis found that treatment with onabotA sig-
niﬁcantly improved sleep quality, relationship with partner
and work life/daily activities. Patients also reported a signiﬁ-
cant decrease in depressed and tired feelings as a result of
bladder problems, as well as a signiﬁcant decrease in how
often they had to use pads and change their underclothes
after treatment with onabotA. To our knowledge, this is the
ﬁrst randomized, placebo-controlled, pooled study to show
the efﬁcacy of onabotA across the speciﬁc questions in the
KHQ that address these practical aspects of daily living.
Few studies have evaluated the impact of CIC on HRQOL
outcomes in OAB patients. Similar to Khan et al.,23 results
from our post-hoc analyses show that CIC use did not dimin-
ish the HRQOL improvements with onabotA. A potential
explanation for this ﬁnding is that, among the minority of
patients who initiated CIC (5.6% overall), it was performed
only an average of 2.3 times/day and thus, the demands of
CIC might seem small to patients compared with the beneﬁt
gained from treatment with onabotA. In addition, a previous
study showed that once patients learn and adhere to the tech-
nique of CIC, they actually report improvements in their
HRQOL scores, possibly because of the additional control
over OAB symptoms that CIC provides.24
The post-hoc analyses in the subgroup by UTI status
showed that UTI somewhat reduced the magnitude of
improvement in HRQOL scores in onabotA-treated patients
with UTI; however, regardless of UTI status, the improve-
ments were clinically relevant (two to ﬁve times the MID)
across all but the General Health domains. The marked
improvements observed in HRQOL despite UTI might be
explained by the fact that UTI is a transient event. Previously
published analyses in this subgroup of patients showed that
regardless of the presence or absence of UTI, onabotA
reduced the daily episodes of UI compared with placebo.25
One limitation of the present analysis was that the HRQOL
assessments in the subgroups were post-hoc, and the sample
sizes of the subgroups were small, hence the results should
be interpreted accordingly. In addition, the HRQOL outcomes
were evaluated by patient-reported questionnaires, and thus
were subjective in nature. Nevertheless, patient-reported mea-
sures are valuable tools used to capture patient perspectives,
and are recognized as an important component in the assess-
ment of OAB treatment efﬁcacy.
In this pooled analysis of OAB patients with UI who were
inadequately managed by ≥1 anticholinergic, the majority of
patients reported treatment beneﬁt after onabotA 100U ther-
apy. Signiﬁcant improvements were demonstrated across indi-
vidual and overall HRQOL outcomes. Notably, these results
were observed regardless of the need for CIC or the occur-
rence of UTI. The results of this study suggest that onabotA isT
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K EVERAERT ET AL.
an effective treatment in OAB patients with UI, and provides
clinically meaningful improvements in patients’ daily lives.
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